Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002739-40
    Sponsor's Protocol Code Number:GLP1_glucose_control
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-07-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2017-002739-40
    A.3Full title of the trial
    Beta cell imaging in type 1 diabetes with stable near-normal and unstable glucose control using PET
    Bètacel imaging bij type 1 diabetes met stabiele vrijwel normale en onstabiele glucoseregulatie met behulp van PET
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The relation between blood glucose control and the number of insulin-producing cells in the body
    De relatie tussen bloedsuikerregulatie en het aantal insuline-producerende cellen in het lichaam
    A.3.2Name or abbreviated title of the trial where available
    GLP1-reg
    GLP1-reg
    A.4.1Sponsor's protocol code numberGLP1_glucose_control
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorRadboud university medical center
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportRadboudumc
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationRadboud university medical center
    B.5.2Functional name of contact pointDepartment of Nuclear Medicine
    B.5.3 Address:
    B.5.3.1Street AddressGeert Grooteplein Zuid 10
    B.5.3.2Town/ cityNijmegen
    B.5.3.3Post code6525 GA
    B.5.3.4CountryNetherlands
    B.5.6E-mailtom.jp.jansen@radboudumc.nl
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Byetta
    D.2.1.1.2Name of the Marketing Authorisation holderEli Lilly Nederland B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name68Ga-NODAGA-[K40]-Exendin-4
    D.3.4Pharmaceutical form Radiopharmaceutical precursor, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous bolus use (Noncurrent)
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product Yes
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Type 1 diabetes
    Type 1 diabetes
    E.1.1.1Medical condition in easily understood language
    Type 1 diabetes
    Suikerziekte type 1
    E.1.1.2Therapeutic area Body processes [G] - Metabolic Phenomena [G03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10067584
    E.1.2Term Type 1 diabetes mellitus
    E.1.2System Organ Class 10027433 - Metabolism and nutrition disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main study objective is to measure residual beta cell mass, indicated by the pancreatic uptake of 68Ga-exendin using quantitative PET, in T1D patients with stable near-normal and unstable glucose control, to improve understanding of the relation between residual beta cell mass and glycemic control.
    Het primaire doel is om residuele bètacel-massa te meten, aangegeven door de uptake van 68Ga-exendin in het pancreas gebruikmakend van kwantitatieve PET, in T1D patiënten met een stabiele vrijwel normale en onstabiele glucoseregulatie, om een beter begrip te krijgen van de relatie tussen residuele bètacel-massa en glycemische regulatie.
    E.2.2Secondary objectives of the trial
    The secondary aim is to correlate the measured residual beta cell mass to the beta cell function that will be determined by a mixed-meal tolerance test.
    Het secundaire doel is om de gemeten residuele bètacel-massa te correleren met de bètacel-functie, die bepaald zal worden door een maaltijdstimulatietest.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    lnclusion criteria: T1D patients with stable near-normal glucose control:
    - Age ≥18 years
    - T1D diagnosed ≥1 year at the start of the study
    - HbA1c <7 (<53 mmol/mol)
    - 17≤ BMI ≤30 kg/m^2
    - No severe hypoglycemic events in the past year and a maximum of 2 severe hypoglycemic events in their entire life.
    - lntact hypoglycemic awareness as assessed by a score of 0 or 1 on the modified Clarke's questionnaire
    - Ability to sign informed consent

    lnclusion criteria: T1D patients with unstable glucose control:
    - Age ≥18 years
    - T1D diagnosed ≥1 year at the start of the study
    - HbA1c >8.5 (>69 mmol/mol)
    - 17≤ BMI ≤30 kg/m^2
    - Minimum of 2 severe hypoglycemic events in the past year or an impaired awareness of hypoglycemia (IHA), as assessed by a score of 3 or more on the modified Clarke's questionnaire (subjects may comply with both criteria, but this is not a requirement)
    - Ability to sign informed consent
    lnclusiecriteria: T1D patiënten met stabiele vrijwel normale glucose regulatie:
    - Leeftijd ≥18 jaar
    - T1D diagnose ≥1 jaar bij de start van de studie
    - HbA1c <7 (<53 mmol/mol)
    - 17≤ BMI ≤30 kg/m^2
    - Geen ernstige hypoglycemische voorvallen in het afgelopen jaar en een maximum van 2 ernstige hypoglycemische voorvallen tijdens het gehele leven
    - lntact hypoglycemisch bewustzijn, beoordeeld met een score van 0 of 1 op de aangepaste Clarke's questionnaire
    - Het vermogen om het toestemmingsformulier te tekenen

    lnclusiecriteria: T1D patiënten met onstabiele glucose regulatie:
    - Leeftijd ≥18 jaar
    - T1D diagnose ≥1 jaar bij de start van de studie
    - HbA1c >8.5 (>69 mmol/mol)
    - 17≤ BMI ≤30 kg/m^2
    - Minimum van 2 ernstige hypoglycemische voorvallen in het afgelopen jaar of een verminderd hypoglycemisch bewustzijn, beoordeeld met een score van 3 of meer op de aangepaste Clarke's questionnaire (proefpersonen mogen aan beide criteria voldoen, maar dit is geen vereiste)
    - Het vermogen om het toestemmingsformulier te tekenen
    E.4Principal exclusion criteria
    Exclusion criteria:
    - Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase lV
    inhibitors
    - Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of the normal range
    - Renal disease defined as MDRD <40 ml/min/1.73 m^2
    - Pregnancy or the wish to become pregnant within 6 months after the study
    - Breastfeeding
    - BMI <17 kg/m^2 or BMI >30 kg/m^2
    - Age <18 years
    - lnability to sign informed consent
    Exclusiecriteria:
    - Eerdere behandeling met synthetisch Exendin (Exenatide, Byetta®) of Dipeptidyl-Peptidase lV inhibitors in de afgelopen 6 maanden
    - Leverziekte, gedefinieerd als een asparaat aminotransferase of alanine aminotransferase waarde van meer dan drie keer de bovengrens van de normaalwaarde
    - Nierziekte, gedefinieerd als een MDRD <40 ml/min/1.73 m^2
    - Zwanger of de wens om zwanger te worden binnen 6 maanden na de studie
    - Geven van borstvoeding
    - BMI <17 kg/m^2 of BMI >30 kg/m^2
    - Leeftijd <18 jaar
    - Het onvermogen om schriftelijke toestemming te geven
    E.5 End points
    E.5.1Primary end point(s)
    The main study objective is to determine residual beta cell mass in T1D patients with stable near-normal and unstable glucose control, as determined by measuring pancreatic uptake of Ga-68-exendin-4, to gain a better understanding of the relation between residual beta cell mass and glycemic control.
    Het primaire doel van de studie is om de residuele bètacel-massa te bepalen met behulp van Ga-68-exendin PET, bij type 1 diabetes patiënten met stabiele vrijwel normale glucoseregulatie en instabiele glucoseregulatie, om een beter begrip krijgen van de relatie tussen residuele bètacel-massa en glycemische regulatie.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 hour after the administration of the tracer
    1 uur na toediening van de tracer
    E.5.2Secondary end point(s)
    The secondary aim is to correlate the measured residual beta cell mass to the beta cell function that will be determined by a mixed-meal tolerance test.
    Het secundaire doel is om de gemeten residuele bètacel-massa aan de bètacel-functie te correleren, de bètacel-functie zal bepaald worden met een maaltijdstimulatie test.
    E.5.2.1Timepoint(s) of evaluation of this end point
    After the analysis of the mixed-meal tolerance test and PET/CT scan
    Na de analyse van de maaltijdstimulatietest en PET/CT scan
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    In this study we will determine the beta cell mass as well as the beta cell function in T1D patients with a different glycemic control. This will give more insight in the relation between beta cell function and mass, which will aid in the selection of patients for innovative treatment aimed at improving beta cell function. Diagnosis of T1D was already done as stated in the inclusion criteria.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Controlegroep: T1D patiënten met stabiele vrijwel normale glucoseregulatie
    Control group: T1D patients with stable near-normal glucose control
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 18
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Geen
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-07-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-07-27
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2021-06-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 02:50:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA